Paige Schmidt’s Post

Here is a quick update for those of you that missed our webinar discussing HealthEZ’s Medical Infusion Carve-Out Program. The presentation is available below and if you have any questions or would like to discuss opportunities feel free to reach out to me.

Phase 2 clinical trial update on NETs! 📊 Lenvatinib and pembrolizumab combo in advanced GI and thoracic NETs showed 10% partial response, with median PFS of 8 months. Also, 60% experienced grade 3 adverse events, leading to dose adjustments or discontinuation. The trial did not show sufficient response to be continued. More details in the article: https://ow.ly/hwrG50R0Vbj #MedEd

🔍 Improve your skills in detecting atrial fibrillation and providing person-centred care! Join our learning programme to empower individuals in self-managing their condition effectively. 👉 Don’t forget to complete Unit 2 of our Fundamentals of Cardiovascular Therapeutics e-course before attending. 🌟 Ready to make a difference? Learn more and register here: https://lnkd.in/eCRckAGU #AtrialFibrillation #HealthcareTraining

🚀 Advancing personalized tissue therapies: VERIGRAFT P-TEV clinical trial update 🚀 We are excited to share progress from our ongoing Phase I/II clinical trial in Europe! Eleven of the planned fifteen patients have now been treated with our Personalized Tissue-Engineered Vein (P-TEV) product, and four of these patients have completed the twelve-month follow-up period. Our trial aims to evaluate P-TEV’s potential to cure chronic venous insufficiency, a condition caused by faulty valves that fail to prevent venous blood backflow. Primary endpoints focus on safety, assessing risks such as infection, mechanical failure, and thrombosis. Secondary endpoints will measure treatment efficacy. “So far, the results are exceeding expectations, confirming safety and showing significant promise for our innovative approach,” said Petter Björquist, CEO of VERIGRAFT. “Our commitment to advancing regenerative medicine and providing personalized treatments that enhance recovery and improve quality of life is yielding encouraging outcomes." 🔗 Click the link in the comments section below to learn more about VERIGRAFT’s innovative tissue therapy technology 👇   #RegenerativeMedicine #ClinicalTrials #HealthInnovation #PersonalizedTherapies #PrecisionMedicine #ChronicVenousInsufficiency #PTEV #Gothenburg #Sweden #VERIGRAFT SwedenBIO CCRM Nordic Business Region Göteborg AB ATMP Sweden SwedenBIO Business Sweden

🔍have you explored the Myeloma and AL Amyloidosis European Clinical Trial Navigator? This online tool helps you find and learn about clinical trials for myeloma and AL amyloidosis in Europe. It supports patients, carers and advocates in making informed decisions about trial participation. Features: Disease-specific search filters Info on trial phases, locations and more Updates on new trials and results Explore now: https://lnkd.in/dDRHsv2Z Watch this video about the MPE Navigator to learn more: https://lnkd.in/dHHjMcz2

Surgical excellence demands dependability in the operating room. Whether it’s for a sentinel lymph node biopsy or the excision of a lesion, the Neoprobe® GDS is the device you can count on for every patient. Find out why the Neoprobe® GDS has been leading the way in gamma detection for over 20 years.* Link: https://ow.ly/MwYc50SiPWA #Mammotome #lymphaticmapping #SurgicalExcellence *Data on file- FDA 510k #K971167 from 1997 based on historical sales data and market size.

Interested in more updates in myelofibrosis? Check out the Journal of Clinical Pathways' Myelofibrosis Resource Center!   Click here for the latest news 👉 https://lnkd.in/e9n_kyMD #JournalOfClinicalPathways #CancerCare #MyelofibrosisResourceCenter #Myelofibrosis

#lungcancer 🩺🚨 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III #nsclc : Phase 1 CLOVER #study 🔍64 pts ORR➡️60.9% mPFS➡️13.4 mo G3-4 AE➡️76.6% G5 AE➡️12.5%‼️ 🩺🚨 Author conclusion sentence: Durvalumab in combination with cCRT was well tolerated, with a manageable safety profile and showed encouraging antitumor activity in patients with unresectable, stage III NSCLC. 🩺🚨 IMO: This is certainly not a well tolerated and manageable toxicity profile!!! We need to abandon this terminology that underestimates toxicity in clinical trial reporting. Furthermore, although there is no control arm, I do not think that this combination would be an effective combination regimen in an unselected patient population. full text in the comment 🔻🔻🔻 #lungcancer

👨🏻⚕️ Healthcare Professionals, New clinical case by Curium Pharma 👉 Role of myocardial perfusion imaging with SPECT in coronary artery disease ✅ Free Registration 🕐 20 minutes 👨🏻⚕️ Hosted by Fabien Hyafil 💻 The presentation will begin with theoretical reminders before exposing an interactive clinical case. It will finish with a summary. Benefit from the expertise of a specialist to:  ✔️ Discuss the value of stress myocardial perfusion imaging with SPECT ✔️ Evaluate patients with stable coronary artery disease Free registration on Invivox via the following link : go2.invivox.com/44fT1bR Curium Pharma

We are excited to share data from the first cohort of the LIGHTHOUSE study, our ongoing Phase I/II clinical trial evaluating our investigational #GeneTherapy ATSN-201 for the treatment of X-linked retinoschisis (#XLRS). For the first time in patients, we have validated the ability of AAV.SPR, our novel spreading #capsid, to spread laterally well beyond the subretinal injection blebs. Additionally, we have demonstrated the ability to safely administer subretinal injections in patients with extensive retinal schisis. Subretinal injection of ATSN-201 was well tolerated in all three patients in the first cohort with two patients showing extensive resolution of schisis beginning at 8 weeks after dosing. Additional and continued resolution of schisis was observed through week 24, the latest time point available. Read more about the data in our press release: https://lnkd.in/eAcpdUHS